Ireland
(State or Other Jurisdiction of Incorporation)
|
001-37977
(Commission File Number)
|
98-1341933
(I.R.S. Employer Identification No.) |
Block 10-1
Blanchardstown Corporate Park, Ballycoolin
Dublin 15, Ireland
(Address of Principal Executive Offices)
|
Not Applicable
(Zip Code)
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Ticker symbol(s)
|
Name of each exchange on
which registered |
American Depositary Shares*
|
AVDL
|
NASDAQ Stock Market LLC
|
Ordinary Shares**
|
(NASDAQ Global Market)
|
*
|
American Depositary Shares may be evidenced by American Depository Receipts. Each American Depositary Share represents one (1) Ordinary
Share.
|
**
|
Nominal value $0.01 per share. Not for trading, but only in connection with the listing of American Depositary Shares.
|
99.1
|
Press release dated October 4, 2019, issued by Avadel Pharmaceuticals plc
|
AVADEL PHARMACEUTICALS PLC
|
||
By:
|
/s/ Phillandas T. Thompson
|
|
Phillandas T. Thompson
Senior Vice President, General Counsel and Corporate Secretary
|
Contacts:
|
Michael F. Kanan
|
|
Chief Financial Officer
|
|
Phone: (636) 449-1844
|
|
Email: mkanan@avadel.com
|
|
|
|
Tim McCarthy
|
|
LifeSci Advisors, LLC
|
|
Phone: (212) 915.2564
|
|
Email: tim@lifesciadvisors.com
|